Novel imaging findings in pyruvate dehydrogenase complex (PDHc) deficiency-Results from a nationwide population-based study.
Leigh-like lesions.
leukoencephalopathy
magnetic resonance imaging
pyruvate dehydrogenase complex deficiency
stroke-like lesions
Journal
Journal of inherited metabolic disease
ISSN: 1573-2665
Titre abrégé: J Inherit Metab Dis
Pays: United States
ID NLM: 7910918
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
19
11
2021
received:
08
10
2021
accepted:
03
12
2021
pubmed:
8
12
2021
medline:
10
5
2022
entrez:
7
12
2021
Statut:
ppublish
Résumé
The vast clinical and radiological spectrum of pyruvate dehydrogenase complex (PDHc) deficiency continues to pose challenges both in diagnostics and disease monitoring. Prompt diagnosis is important to enable early initiation of ketogenic diet. The patients were recruited from an ongoing population-based study in Sweden. All patients with a genetically confirmed diagnosis who had been investigated with an MRI of the brain were included. Repeated investigations were assessed to study the evolution of the MRI changes. Sixty-two MRI investigations had been performed in 34 patients (23 females). The genetic cause was mutations in PDHA1 in 29, PDHX and DLAT in 2 each, and PDHB in 1. The lesions were prenatal developmental in 16, prenatal clastic in 18, and postnatal clastic in 15 individuals. Leigh-like lesions with predominant involvement of globus pallidus were present in 12, while leukoencephalopathy was present in 6 and stroke-like lesions in 3 individuals. A combination of prenatal developmental and clastic lesions was present in 15 individuals. In addition, one male with PDHA1 also had postnatal clastic lesions. The most common lesions found in our study were agenesis or hypoplasia of corpus callosum, ventriculomegaly, or Leigh-like lesions. Furthermore, we describe a broad spectrum of other MRI changes that include leukoencephalopathy and stroke-like lesions. We argue that a novel important clue, suggesting the possibility of PDHc deficiency on MRI scans, is the simultaneous presence of multiple lesions on MRI that have occurred during different phases of brain development.
Substances chimiques
Pyruvate Dehydrogenase Complex
0
Pyruvate Dehydrogenase (Lipoamide)
EC 1.2.4.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
248-263Informations de copyright
© 2021 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.
Références
Gray L, Tompkins S, Taylor E. Regulation of pyruvate metabolism and human disease. Cell Mol Life Sci. 2014;71:2577-2604.
Robinson BH, Macmillan H, Petrova-Benedict R, Sherwood WG. Variable clinical presentation in patients with defective E 1 component of pyruvate dehydrogenase complex. J Pediatr. 1987;111:525-533.
Patel KP, O'Brien TW, Subramony SH, Shuster J, Stacpoole PW. The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients. Mol Genet Metab. 2012;105:34-43.
Sofou K, Dahlin M, Hallböök T, Lindefeldt M, Viggedal G, Darin N. Ketogenic diet in pyruvate dehydrogenase complex deficiency: short- and long-term outcomes. J Inherit Metab Dis. 2017;40:237-245.
Debrosse SD, Okajima K, Zhang S, et al. Spectrum of neurological and survival outcomes in pyruvate dehydrogenase complex (PDC) deficiency: lack of correlation with genotype. Mol Genet Metab. 2012;107:394-402.
BARNERIAS C, SAUDUBRAY J-M, TOUATI G, et al. Pyruvate dehydrogenase complex deficiency: four neurological phenotypes with differing pathogenesis. Dev Med Child Neurol. 2010;52:e1-e9.
Lissens W, De Meirleir L, Seneca S, et al. Mutations in the X-linked pyruvate dehydrogenase (E1) alpha subunit gene (PDHA1) in patients with a pyruvate dehydrogenase complex deficiency. Hum Mutat. 2000;15:209-219.
Pavlu-Pereira H, Silva MJ, Florindo C, et al. Pyruvate dehydrogenase complex deficiency: updating the clinical, metabolic and mutational landscapes in a cohort of Portuguese patients. Orphanet J Rare Dis. 2020;15:298.
Shin HK, Grahame G, McCandless SE, Kerr DS, Bedoyan JK. Enzymatic testing sensitivity, variability and practical diagnostic algorithm for pyruvate dehydrogenase complex (PDC) deficiency. Mol Genet Metab. 2017;122:61-66.
De Meirleir L. Defects of pyruvate metabolism and the Krebs cycle. Journal of Child Neurology. 2002;17(Suppl 3):3S26.
Ah Mew N, Loewenstein JB, Kadom N, et al. MRI features of 4 female patients with pyruvate dehydrogenase E1 alpha deficiency. Pediatr Neurol. 2011;45:57-59.
Shelkowitz E, Ficicioglu C, Stence N, Van Hove J, Larson A. Serial magnetic resonance imaging (MRI) in pyruvate dehydrogenase complex deficiency. J Child Neurol. 2020;35:137-145.
Dahl HH. Pyruvate dehydrogenase E1 alpha deficiency: males and females differ yet again. Am J Hum Genet. 1995;56:553-557.
Soares-Fernandes J, Teixeira-Gomes R, Cruz R, et al. Neonatal pyruvate dehydrogenase deficiency due to a R302H mutation in the PDHA1 gene: MRI findings. Pediatr Radiol. 2008;38:559-562.
Bonfante E, Koenig M, Adejumo R, Perinjelil V, Riascos R. The neuroimaging of Leigh syndrome: case series and review of the literature. Pediatr Radiol. 2016;46:443-451.
Edwards TJ, Sherr EH, Barkovich AJ, Richards LJ. Clinical, genetic and imaging findings identify new causes for corpus callosum development syndromes. Brain. 2014;137:1579-1613.
Barkovich AJ. Concepts of myelin and myelination in neuroradiology. AJNR Am J Neuroradiol. 2000;21:1099-1109.
Barkovich A. Magnetic resonance techniques in the assessment of myelin and myelination. J Inherit Metab Dis. 2005;28:311-343.
Sofou K, Steneryd K, Wiklund L-M, Tulinius M, Darin N. MRI of the brain in childhood-onset mitochondrial disorders with central nervous system involvement. Mitochondrion. 2013;13(4):13-371.
Gordon HB, Letsou A, Bonkowsky JL. The leukodystrophies. Semin Neurol. 2014;34:312-320.
Folkerth RD. The neuropathology of acquired pre- and perinatal brain injuries. Semin Diagn Pathol. 2007;24:48-57.
Brown RM, Brown GK. Prenatal diagnosis of pyruvate dehydrogenase E1 alpha subunit deficiency. Prenat Diagn. 1994;14:435-441.
Takakubo F, Dahl H-HM. Analysis of pyruvate dehydrogenase expression in embryonic mouse brain: localization and developmental regulation. Brain Res Dev Brain Res. 1994;77:63-76.
Pirot N, Crahes M, Adle-Biassette H, et al. Phenotypic and neuropathological characterization of fetal pyruvate dehydrogenase deficiency. J Neuropathol Exp Neurol. 2016;75:227-238.
Levin S, Roecklein B, Mukherjee A. Intrauterine growth retardation caused by dietary biotin and thiamine deficiency in the rat. Res Exp Med. 1985;185:375-381.
Pavlakis SG, Phillips PC, Dimauro S, De Vivo DC, Rowland LP. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol. 1984;16:481-488.
Gropman A. Neuroimaging in mitochondrial disorders. Neurotherapeutics. 2013;10:273-285.
Leinonen V, Vanninen R, Rauramaa T. Chapter 4 - raised intracranial pressure and brain edema. In: Kovacs GG, Alafuzoff I, eds. Handbook of Clinical Neurology. Amsterdam, Netherlands: Elsevier; 2018:25-37.
Darin N, Oldfors A, Moslemi AR, Holme E, Tulinius M. The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities. Ann Neurol. 2001;49:377-383.
Alves C, Teixeira SR, Martin-Saavedra JS, et al. Pediatric Leigh syndrome: neuroimaging features and genetic correlations. Ann Neurol. 2020;88:218-232.
Head RA, Brown RM, Zolkipli Z, et al. Clinical and genetic spectrum of pyruvate dehydrogenase deficiency: Dihydrolipoamide acetyltransferase (E2) deficiency. Ann Neurol. 2005;58:234-241.
Lissens W, Vreken P, Barth PG, et al. Cerebral palsy and pyruvate dehydrogenase deficiency: identification of two new mutations in the E1alpha gene. Eur J Pediatr. 2000;158:853-857.
Pliss L, Hausknecht KA, Stachowiak MK, Dlugos CA, Richards JB, Patel MS. Cerebral developmental abnormalities in a mouse with systemic pyruvate dehydrogenase deficiency.(research article). PLoS ONE. 2013;8:e67473.